[
  {
    "ts": null,
    "headline": "BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial",
    "summary": "BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.",
    "url": "https://finnhub.io/api/news?id=fecdf94128ee4bc040bf061558857b4de3ac98a6599846439cb0fba1a14ac3a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744740390,
      "headline": "BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial",
      "id": 133928013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.",
      "url": "https://finnhub.io/api/news?id=fecdf94128ee4bc040bf061558857b4de3ac98a6599846439cb0fba1a14ac3a5"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?",
    "summary": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]",
    "url": "https://finnhub.io/api/news?id=8132a595cb9db93983e7f8b12b83309d69fae82a6f27f2ba877a49d57f54797e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744738726,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?",
      "id": 133928014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]",
      "url": "https://finnhub.io/api/news?id=8132a595cb9db93983e7f8b12b83309d69fae82a6f27f2ba877a49d57f54797e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=2366e8ac1d4e92eec5b55e96f7774b8c7186018c260a645279831371ac97653f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744735020,
      "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "id": 133948763,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=2366e8ac1d4e92eec5b55e96f7774b8c7186018c260a645279831371ac97653f"
    }
  },
  {
    "ts": null,
    "headline": "BMY Down on Heart Drug Camzyos Failure in Late-Stage Study",
    "summary": "Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.",
    "url": "https://finnhub.io/api/news?id=429a630196117ea8c63af6bafe1b0f4e5a27f914497d0a48de3e4e364495893e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744719420,
      "headline": "BMY Down on Heart Drug Camzyos Failure in Late-Stage Study",
      "id": 133922316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.",
      "url": "https://finnhub.io/api/news?id=429a630196117ea8c63af6bafe1b0f4e5a27f914497d0a48de3e4e364495893e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires?",
    "summary": "We recently published a list of the 10 Best Value Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best value dividend stocks. Dividends, though sometimes underappreciated, have significantly contributed to long-term investor gains. Between 1960 and the end […]",
    "url": "https://finnhub.io/api/news?id=c4c7c85677b9b0556ea2c043092426f5babd7d45d9f3f88bab45b768dd44cd80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744716915,
      "headline": "Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires?",
      "id": 133922317,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Value Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best value dividend stocks. Dividends, though sometimes underappreciated, have significantly contributed to long-term investor gains. Between 1960 and the end […]",
      "url": "https://finnhub.io/api/news?id=c4c7c85677b9b0556ea2c043092426f5babd7d45d9f3f88bab45b768dd44cd80"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers stumbles in bid to widen heart drug’s use",
    "summary": "Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether other drugs like it would similarly struggle in testing.",
    "url": "https://finnhub.io/api/news?id=a04a2bf12d299afb6d93a191ee56fa51d5c118214adc0c176b5e322475dc60fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744711200,
      "headline": "Bristol Myers stumbles in bid to widen heart drug’s use",
      "id": 133922318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether other drugs like it would similarly struggle in testing.",
      "url": "https://finnhub.io/api/news?id=a04a2bf12d299afb6d93a191ee56fa51d5c118214adc0c176b5e322475dc60fa"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: inconclusive phase III trial for Camzyos",
    "summary": "Bristol Myers Squibb has announced that its phase 3 trial evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy did not meet its two primary...",
    "url": "https://finnhub.io/api/news?id=112f50691c1d6c2cba6b33f977aea6586be46fdb99c6e662588e6a59f9b9c433",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744707619,
      "headline": "Bristol Myers: inconclusive phase III trial for Camzyos",
      "id": 133920881,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb has announced that its phase 3 trial evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy did not meet its two primary...",
      "url": "https://finnhub.io/api/news?id=112f50691c1d6c2cba6b33f977aea6586be46fdb99c6e662588e6a59f9b9c433"
    }
  }
]